Introducing the innovations we plan to do in the Netherlands X-omics Initative, together with other X-omics consortium members, at a dedicated X-omics workshop at the annual congres of the Netherlands Chemistry society.
2016 11-15 Lygature partnership meetup, Utrecht, Alain van GoolAlain van Gool
Contribution to the opening of the Joint Innovation Mile in the Beatrix building in Utrecht, home of the offices of Lygature, HealthRI, BBMRI-NL and others to follow.
2018 06-13 Benelux Precision Medicine Forum, Utrecht, Alain van GoolAlain van Gool
Professor Alain van Gool discusses innovations in using molecular insights for personalized health and medicine. He describes how genomics, metabolomics, glycomics, and other omics technologies can provide personalized diagnoses and therapies. Integrating these multi-omics approaches will lead to new disease mechanisms and treatments being discovered.
2018 11-26 KNAW-AcTI symposium Personalized Health, Amsterdam, Alain van GoolAlain van Gool
Lecture at a citizen discussion evening, reviewing the promises and (ethical) considerations of technology developments to support personalized health, organised by the Royal Academy of Sciences and the Netherlands Academy of Technology and Innovation.
Purpose of the Call:
Review the results of the National VTE audit
Discuss lessons learned from the audit – strengths and areas for improvement
Gather ideas for future steps for implementation of VTE prophylaxis
Dr. Deepanker Tewari - Antibiotic Stewardship Update ProgressJohn Blue
Antibiotic Stewardship Update Progress - Dr. Eric Moore, Technical Director, Norbrook, Inc.; Dr. Michael Costin, Assistant Director, Division of Animal & Public Health, AVMA; Dr. Andrew T. Maccabe, Chief Executive Officer, AAVMC; Dr. Deepanker Tewari, Director, Pennsylvania Department of Agriculture Veterinary Laboratory, from the 2017 NIAA Antibiotic Symposium - Antibiotic Stewardship: Collaborative Strategy for Animal Agriculture and Human Health, October 31 - November 2, 2017, Herndon, Virginia, USA.
More presentations at http://www.swinecast.com/2017-niaa-antibiotic-symposium-antibiotic-stewardship
Early and late phase clinical trial potential and The Phase I Unit projec...Tristan Azbej, PhD
The document discusses a potential partnership between the Medical Center of Hungarian Defense Forces (MCHDF) and SGS Clinical Research to establish an early phase clinical trial unit at MCHDF. Key points include:
- MCHDF is one of the largest hospital complexes in Hungary and currently participates in oncology clinical trials. SGS Clinical Research has extensive experience conducting early phase oncology trials.
- The partnership would involve SGS providing resources like staffing, standard operating procedures, and operational support to establish an early phase unit at MCHDF and maximize its ability to participate in phase I/II trials.
- This satellite unit model aims to increase patient access to early phase studies while ensuring proper resources and
2016 11-15 Lygature partnership meetup, Utrecht, Alain van GoolAlain van Gool
Contribution to the opening of the Joint Innovation Mile in the Beatrix building in Utrecht, home of the offices of Lygature, HealthRI, BBMRI-NL and others to follow.
2018 06-13 Benelux Precision Medicine Forum, Utrecht, Alain van GoolAlain van Gool
Professor Alain van Gool discusses innovations in using molecular insights for personalized health and medicine. He describes how genomics, metabolomics, glycomics, and other omics technologies can provide personalized diagnoses and therapies. Integrating these multi-omics approaches will lead to new disease mechanisms and treatments being discovered.
2018 11-26 KNAW-AcTI symposium Personalized Health, Amsterdam, Alain van GoolAlain van Gool
Lecture at a citizen discussion evening, reviewing the promises and (ethical) considerations of technology developments to support personalized health, organised by the Royal Academy of Sciences and the Netherlands Academy of Technology and Innovation.
Purpose of the Call:
Review the results of the National VTE audit
Discuss lessons learned from the audit – strengths and areas for improvement
Gather ideas for future steps for implementation of VTE prophylaxis
Dr. Deepanker Tewari - Antibiotic Stewardship Update ProgressJohn Blue
Antibiotic Stewardship Update Progress - Dr. Eric Moore, Technical Director, Norbrook, Inc.; Dr. Michael Costin, Assistant Director, Division of Animal & Public Health, AVMA; Dr. Andrew T. Maccabe, Chief Executive Officer, AAVMC; Dr. Deepanker Tewari, Director, Pennsylvania Department of Agriculture Veterinary Laboratory, from the 2017 NIAA Antibiotic Symposium - Antibiotic Stewardship: Collaborative Strategy for Animal Agriculture and Human Health, October 31 - November 2, 2017, Herndon, Virginia, USA.
More presentations at http://www.swinecast.com/2017-niaa-antibiotic-symposium-antibiotic-stewardship
Early and late phase clinical trial potential and The Phase I Unit projec...Tristan Azbej, PhD
The document discusses a potential partnership between the Medical Center of Hungarian Defense Forces (MCHDF) and SGS Clinical Research to establish an early phase clinical trial unit at MCHDF. Key points include:
- MCHDF is one of the largest hospital complexes in Hungary and currently participates in oncology clinical trials. SGS Clinical Research has extensive experience conducting early phase oncology trials.
- The partnership would involve SGS providing resources like staffing, standard operating procedures, and operational support to establish an early phase unit at MCHDF and maximize its ability to participate in phase I/II trials.
- This satellite unit model aims to increase patient access to early phase studies while ensuring proper resources and
poster O.Apryshkina Zoom Zoom 18 May 2016 FinalOlga Apryshkina
This document summarizes the manufacturing capabilities and population coverage of CAR T cell therapy across several European countries based on four key factors: 1) manufacturing capability, 2) population covered, 3) quality assurance, and 4) resources. The UK and Germany scored highest in population covered at 95% and 88% respectively due to standardized manufacturing processes, clinical/regulatory expertise, and government/financial support. Across the EU, an average of 46% of the population could potentially be covered based on current manufacturing capacity for clinical research trials, though this varies widely between countries from 0-194%. Recommendations include increasing GMP manufacturing labs, standardizing regulations, and boosting funding for gene therapy research.
National Comparative Audit of Lower Gastrointestinal Bleeding and the Use of Blood: Findings and Interpretations
This audit examined practice and outcomes for 2,528 patients admitted with lower gastrointestinal bleeding (LGIB) across 143 UK hospitals. Key findings included inappropriate transfusion in 27% of patients, only 26% receiving endoscopy within 24 hours, and 49% having no investigations to identify the bleeding source. Performance was compared against 17 evidence-based standards, identifying opportunities for improvement particularly around medicines management and timely investigation. Interpretations highlighted the benefits of centralized specialized care for LGIB patients, including more consistent guideline-based care, regular auditing, teaching and lower costs through reduced variation.
CADTH is a not-for-profit organization funded by Health Canada and provincial/territorial governments. It conducts health technology assessments of drugs and devices, employs 190 staff in Ottawa and Toronto, and is involved globally in health technology assessment. CADTH provides decision-makers with objective evidence on clinical and cost effectiveness to promote optimal use of health technologies and build domestic assessment capacity. While quality-adjusted life years are important, health technology assessment considers additional societal perspectives. Adaptive licensing and pathways prospectively plan iterative evidence gathering and regulatory/coverage adaptations to balance early access and assessment of uncertainties using real-world data across sectors.
This document discusses value-based pricing and "innovative agreements" between the pan-Canadian Pharmaceutical Alliance (pCPA) and pharmaceutical manufacturers. It notes that performance-based agreements that tie the price of drugs to health outcomes present both challenges and opportunities. Challenges include implementing systems to track outcomes and determining which outcomes are measurable and attributable to the drug. Opportunities include structuring agreements for small patient populations and tying rebates to uncertainty in outcomes. The document argues that value-based pricing requires involvement from public drug plans, patients, and manufacturers to address these challenges and realize the opportunities.
InfCareHIV is a clinical decision support system and quality assurance registry for HIV care in Sweden. It covers over 99% of HIV patients nationally, with data on 7838 living patients and 12936 total patients registered. The system is used at each patient visit to automatically transfer lab and quality of life data between clinics. It produces real-time statistics on HIV care in Sweden and delivers anonymized data to international collaborators for research. InfCareHIV also supports pharmaceutical studies through patient identification and data sharing.
Mr James Downie, CEO, presented on the topic 'Moving towards value based funding' at the Healthcare reform, funding and innovation conference, hosted by AventEdge on 27 June 2017.
Rare Disease Drug Development Solutions Info Sheet Covance
This document discusses Covance's rare disease drug development solutions. It notes that while over 7,000 rare diseases exist, only about 200 approved therapies are available. Covance recognizes the importance of developing therapies for high unmet medical needs. Their comprehensive approach integrates capabilities across Covance, LabCorp, and Chiltern to address the complexities of rare disease drug development from early stages through clinical trials. This includes therapeutic expertise, patient engagement, regulatory strategy, and clinical operations support. The goal is a truly patient-centric approach that eases burdens on sites and patients.
Aligning on Patient Outcomes - How Market Dynamics Can Facilitate RWD SolutionsPAREXEL International
This document discusses how real-world data can be used to better understand patient outcomes. It notes that legislation, technology advances, and a shift toward valuing outcomes over volume are accelerating the focus on using real-world data to determine what treatment approaches improve patient outcomes. The document outlines challenges to using real-world data like data quality issues and privacy concerns, and proposes strategies like using hybrid study designs that combine electronic medical record data with traditional clinical trial data collection to help overcome these challenges. Finally, it emphasizes that solutions in this area will need to be developed incrementally while protecting patient privacy and gaining regulatory acceptance.
Mr James Downie, CEO, presented on the topic 'Emergency care costing study and classification development' at the 9th Annual Emergency Department Management Conference, hosted by informa on 31 July 2017.
2017 05-18 Radboudumc Information Management Inspiration Point, Nijmegen, Ala...Alain van Gool
The document discusses the validation of interleukin-8 (IL-8) as a biomarker for melanoma. A study was conducted using 59 melanoma tumor tissue samples and matching serum and plasma to validate that IL-8 is elevated in melanoma. However, the results were inconsistent, as IL-8 protein levels appeared sensitive to freeze-thawing of samples. The author advocates for increasing the quality rather than quantity of biomarker research through improved collaboration to ensure better data and validation.
2017 11-28 European Alliance for Personalised Medicine Congressm 2017, Belfas...Alain van Gool
Lecture to outline the added value of intergrating genomics with proteomics, glycomics and metabolomics to create novel personalized diagnostics and drive personalised healthcare.
2017 10-06 Biomarker Development Center conference, Rotterdam, Alain van GoolAlain van Gool
Lecture at the Biomarker development Center conference on biomarker validation in Rotterdam, outlining opportunities in translational biomarkers but also steps that need to be taken still.
2017 09-20 HUPO2017, Dublin, Alain van Gool withsupplAlain van Gool
Keynote lecture at the HUPO 2017 in Dublin, focussing on our innovations in translational omics for applications in our personalized healthcare at Radboudumc.
2019 06-19 Dutch association for clinical chemistry and laboratory medicine -...Alain van Gool
Sharing my views on how X-omics biomarker analyses through next gen sequencing and mass spectrometry will change the landscape of diagnostics and clinical chemistry in the near future.
2022-10-12 The future of population health_Alain van Gool.pdfAlain van Gool
1) Exponential developments in omics technologies like genomics, proteomics, and metabolomics are driving more personalized approaches to healthcare.
2) Mass spectrometry methods have been developed to sensitively detect minimal residual disease in multiple myeloma patients from plasma samples, allowing for dynamic monitoring and earlier detection of relapse compared to traditional methods.
3) Large-scale multi-omics studies incorporating data from various sources can provide a more holistic view of health and disease at both the individual and population levels, supporting personalized prevention and treatment approaches.
tranSMART Community Meeting 5-7 Nov 13 - Session 3: The TraIT user stories fo...David Peyruc
This document provides an overview of the TraIT project and existing demonstrators using tranSMART. It discusses the TraIT roadmap and user stories being implemented at the Netherlands Cancer Institute. Key points include:
- TraIT aims to support translational research through integrated data and tools across clinical, imaging, biobanking and experimental domains.
- Existing demonstrators using tranSMART include DeCoDe (colorectal cancer) and PCMM (prostate cancer).
- The roadmap involves enhancing tranSMART functionality based on user needs and integrating additional data sources.
- At NKI, tranSMART will provide an integrated research data warehouse with clinical and research data from various sources and departments.
2018 08-16 Masterclass Advances in Genomics Research, ErasmusMC, Rotterdam, A...Alain van Gool
Masterclass in the ErasmusMC Summerschool 'Advances in Genomics Research' for an enthousiastic group of students and professionals, talkiing about 'X-omics in Personalized Healthcare'.
2019 02-21 Oxford Global 14th Biomarker Congress, Manchester, Alain van GoolAlain van Gool
1. Professor Alain van Gool presented on using clinical x-omics to drive personalized healthcare.
2. He described case studies where combining different omic approaches like genomics, metabolomics, and glycomics led to novel disease mechanisms and therapies for rare genetic diseases.
3. Van Gool advocated for increased collaboration and standardization of omic technologies to advance precision medicine and bring clinical multi-omics to higher diagnostic and therapeutic levels.
poster O.Apryshkina Zoom Zoom 18 May 2016 FinalOlga Apryshkina
This document summarizes the manufacturing capabilities and population coverage of CAR T cell therapy across several European countries based on four key factors: 1) manufacturing capability, 2) population covered, 3) quality assurance, and 4) resources. The UK and Germany scored highest in population covered at 95% and 88% respectively due to standardized manufacturing processes, clinical/regulatory expertise, and government/financial support. Across the EU, an average of 46% of the population could potentially be covered based on current manufacturing capacity for clinical research trials, though this varies widely between countries from 0-194%. Recommendations include increasing GMP manufacturing labs, standardizing regulations, and boosting funding for gene therapy research.
National Comparative Audit of Lower Gastrointestinal Bleeding and the Use of Blood: Findings and Interpretations
This audit examined practice and outcomes for 2,528 patients admitted with lower gastrointestinal bleeding (LGIB) across 143 UK hospitals. Key findings included inappropriate transfusion in 27% of patients, only 26% receiving endoscopy within 24 hours, and 49% having no investigations to identify the bleeding source. Performance was compared against 17 evidence-based standards, identifying opportunities for improvement particularly around medicines management and timely investigation. Interpretations highlighted the benefits of centralized specialized care for LGIB patients, including more consistent guideline-based care, regular auditing, teaching and lower costs through reduced variation.
CADTH is a not-for-profit organization funded by Health Canada and provincial/territorial governments. It conducts health technology assessments of drugs and devices, employs 190 staff in Ottawa and Toronto, and is involved globally in health technology assessment. CADTH provides decision-makers with objective evidence on clinical and cost effectiveness to promote optimal use of health technologies and build domestic assessment capacity. While quality-adjusted life years are important, health technology assessment considers additional societal perspectives. Adaptive licensing and pathways prospectively plan iterative evidence gathering and regulatory/coverage adaptations to balance early access and assessment of uncertainties using real-world data across sectors.
This document discusses value-based pricing and "innovative agreements" between the pan-Canadian Pharmaceutical Alliance (pCPA) and pharmaceutical manufacturers. It notes that performance-based agreements that tie the price of drugs to health outcomes present both challenges and opportunities. Challenges include implementing systems to track outcomes and determining which outcomes are measurable and attributable to the drug. Opportunities include structuring agreements for small patient populations and tying rebates to uncertainty in outcomes. The document argues that value-based pricing requires involvement from public drug plans, patients, and manufacturers to address these challenges and realize the opportunities.
InfCareHIV is a clinical decision support system and quality assurance registry for HIV care in Sweden. It covers over 99% of HIV patients nationally, with data on 7838 living patients and 12936 total patients registered. The system is used at each patient visit to automatically transfer lab and quality of life data between clinics. It produces real-time statistics on HIV care in Sweden and delivers anonymized data to international collaborators for research. InfCareHIV also supports pharmaceutical studies through patient identification and data sharing.
Mr James Downie, CEO, presented on the topic 'Moving towards value based funding' at the Healthcare reform, funding and innovation conference, hosted by AventEdge on 27 June 2017.
Rare Disease Drug Development Solutions Info Sheet Covance
This document discusses Covance's rare disease drug development solutions. It notes that while over 7,000 rare diseases exist, only about 200 approved therapies are available. Covance recognizes the importance of developing therapies for high unmet medical needs. Their comprehensive approach integrates capabilities across Covance, LabCorp, and Chiltern to address the complexities of rare disease drug development from early stages through clinical trials. This includes therapeutic expertise, patient engagement, regulatory strategy, and clinical operations support. The goal is a truly patient-centric approach that eases burdens on sites and patients.
Aligning on Patient Outcomes - How Market Dynamics Can Facilitate RWD SolutionsPAREXEL International
This document discusses how real-world data can be used to better understand patient outcomes. It notes that legislation, technology advances, and a shift toward valuing outcomes over volume are accelerating the focus on using real-world data to determine what treatment approaches improve patient outcomes. The document outlines challenges to using real-world data like data quality issues and privacy concerns, and proposes strategies like using hybrid study designs that combine electronic medical record data with traditional clinical trial data collection to help overcome these challenges. Finally, it emphasizes that solutions in this area will need to be developed incrementally while protecting patient privacy and gaining regulatory acceptance.
Mr James Downie, CEO, presented on the topic 'Emergency care costing study and classification development' at the 9th Annual Emergency Department Management Conference, hosted by informa on 31 July 2017.
2017 05-18 Radboudumc Information Management Inspiration Point, Nijmegen, Ala...Alain van Gool
The document discusses the validation of interleukin-8 (IL-8) as a biomarker for melanoma. A study was conducted using 59 melanoma tumor tissue samples and matching serum and plasma to validate that IL-8 is elevated in melanoma. However, the results were inconsistent, as IL-8 protein levels appeared sensitive to freeze-thawing of samples. The author advocates for increasing the quality rather than quantity of biomarker research through improved collaboration to ensure better data and validation.
2017 11-28 European Alliance for Personalised Medicine Congressm 2017, Belfas...Alain van Gool
Lecture to outline the added value of intergrating genomics with proteomics, glycomics and metabolomics to create novel personalized diagnostics and drive personalised healthcare.
2017 10-06 Biomarker Development Center conference, Rotterdam, Alain van GoolAlain van Gool
Lecture at the Biomarker development Center conference on biomarker validation in Rotterdam, outlining opportunities in translational biomarkers but also steps that need to be taken still.
2017 09-20 HUPO2017, Dublin, Alain van Gool withsupplAlain van Gool
Keynote lecture at the HUPO 2017 in Dublin, focussing on our innovations in translational omics for applications in our personalized healthcare at Radboudumc.
2019 06-19 Dutch association for clinical chemistry and laboratory medicine -...Alain van Gool
Sharing my views on how X-omics biomarker analyses through next gen sequencing and mass spectrometry will change the landscape of diagnostics and clinical chemistry in the near future.
2022-10-12 The future of population health_Alain van Gool.pdfAlain van Gool
1) Exponential developments in omics technologies like genomics, proteomics, and metabolomics are driving more personalized approaches to healthcare.
2) Mass spectrometry methods have been developed to sensitively detect minimal residual disease in multiple myeloma patients from plasma samples, allowing for dynamic monitoring and earlier detection of relapse compared to traditional methods.
3) Large-scale multi-omics studies incorporating data from various sources can provide a more holistic view of health and disease at both the individual and population levels, supporting personalized prevention and treatment approaches.
tranSMART Community Meeting 5-7 Nov 13 - Session 3: The TraIT user stories fo...David Peyruc
This document provides an overview of the TraIT project and existing demonstrators using tranSMART. It discusses the TraIT roadmap and user stories being implemented at the Netherlands Cancer Institute. Key points include:
- TraIT aims to support translational research through integrated data and tools across clinical, imaging, biobanking and experimental domains.
- Existing demonstrators using tranSMART include DeCoDe (colorectal cancer) and PCMM (prostate cancer).
- The roadmap involves enhancing tranSMART functionality based on user needs and integrating additional data sources.
- At NKI, tranSMART will provide an integrated research data warehouse with clinical and research data from various sources and departments.
2018 08-16 Masterclass Advances in Genomics Research, ErasmusMC, Rotterdam, A...Alain van Gool
Masterclass in the ErasmusMC Summerschool 'Advances in Genomics Research' for an enthousiastic group of students and professionals, talkiing about 'X-omics in Personalized Healthcare'.
2019 02-21 Oxford Global 14th Biomarker Congress, Manchester, Alain van GoolAlain van Gool
1. Professor Alain van Gool presented on using clinical x-omics to drive personalized healthcare.
2. He described case studies where combining different omic approaches like genomics, metabolomics, and glycomics led to novel disease mechanisms and therapies for rare genetic diseases.
3. Van Gool advocated for increased collaboration and standardization of omic technologies to advance precision medicine and bring clinical multi-omics to higher diagnostic and therapeutic levels.
2013-10-23 DTL Next Generation Life Sciences Event, UtrechtAlain van Gool
This document summarizes a case study on identifying microRNA targets for miRNA-based cancer therapeutics. Researchers from Radboud University Medical Center, TNO, and InteRNA collaborated using various omics technologies. They screened 1120 miRNAs to identify those that inhibit epithelial-to-mesenchymal transition and cancer cell invasion/metastasis. Proteomics and transcriptomics were used to validate miRNA targets, and CyTargetLink integrated the multi-omics data. The collaboration aimed to improve understanding of miRNA effects on cancer metastasis through integrated systems biology approaches.
2016 11-01 Biomarker Agora, Copenhagen, Alain van GoolAlain van Gool
This document discusses the development and validation of clinical molecular biomarkers. It begins with an example of how the B-RAFV600E mutation in melanoma can be used for personalized medicine approaches. It then describes efforts to validate interleukin-8 (IL-8) as a biomarker for ERK pathway inhibition, which involved extensive biomarker profiling and validation studies but ultimately found the data to be irreproducible. The document emphasizes the need for improved biomarker validation practices and increased collaboration to address gaps between biomarker discovery and clinical application.
2015 12-09 Opening Radboud Translational Medicine, Nijmegen, Alain van GoolAlain van Gool
Keynote opening lecture at the grand opening of our new cyclotron facility, embedded in Radboud Translational Medicine and part of our Radboudumc Technology Centers. See http://www.radboudtranslationalmedicine.nl/nl/ for details.
2018 11-02 Healthy Brain Cohort progress meeting, Nijmegen, Alain van GoolAlain van Gool
Highlights and anecdotes from my experiences in interdisciplinary research in big data for personalized healthcare whilst working in Europe, USA and Singapore
2018 11-28 SAB Interreg BIC project Baltic Sea Region, Copenhagen, Alain van ...Alain van Gool
Overview of the current challenges in biomarker commercialisation, to kick off the scientific advisory board meeting with the multidisciplinary Interreg BIC project team.
2015 09-14 Precision Medicine 2015, London, Alain van GoolAlain van Gool
Outline of my view hoe personalized health(care) is more than just targeted medicines, also including personal motivation and actions towards disease prevention. It also outlines 4 key factors that should be in order for optimal personalized health(care): 1. start with patients first, 2. Accelerate translation research to application, 3. Copy best practice, 4. Spread the word.
2023-11-09 HealthRI Biobanking day_Amsterdam_Alain van Gool.pdfAlain van Gool
Examples of lessons learned in Omics-based biomarker studies from myself and colleagues in X-omics and EATRIS, for an audience of biobankers, researchers and diagnostic/clinical chemistry experts.
2014 07-08 Selectbio Biomarkers 2014, CambridgeAlain van Gool
The document discusses biomarkers in personalized healthcare from discovery to clinical diagnostics, providing an overview of the speaker's experience in academia, pharmaceutical industry, and applied research focusing on biomarkers and omics technologies. It also describes the Radboud University Medical Center's focus on personalized healthcare through its technology centers and biomarker research on conditions like metabolic syndrome. The discussion emphasizes how biomarkers are evolving from diagnosis to tools that enable personalized and participatory healthcare approaches.
2014 02-24 Oxford Global biomarker congress, ManchesterAlain van Gool
This document summarizes a presentation given by Alain van Gool on biomarkers in a changing world. It discusses the shift from personalized medicine to personalized healthcare, which takes a more holistic systems view of an individual. It also notes disruptive technologies that can accelerate biomarker development and the need to translate biomarkers into useful tools. Throughout, it provides examples of challenges like tumor heterogeneity and factors beyond genetics that influence disease and response to treatment.
Similar to 2018 12-04 CHAINS X-omics workshop lecture, Veldhoven, Alain van Gool (20)
2023-11-14 Biomarkers Europe 2023, Berlin, Alain van Gool.pdfAlain van Gool
Lecture at the Biomarkers Europe 2023 conference for an audience of pharma scientists and omics/data solution providers. I outlined several initiatives of potential interest and discussed development of our sensitive personalized clinical biomarker test for minimal residual disease monitoring in multiple myeloma.
2023-04-20 EATRIS-Plus Summerschool, Lisbon, Alain van GoolAlain van Gool
Closing keynote lecture at the EATRIS-Plus summerschool on personalised medicine, outlining developments, opportunities, challenges and recommendations to do next in this exciting era of personalised medicine.
2022-11-23 DTL Future of data-driven life sciences, Utrecht, Alain van Gool.pdfAlain van Gool
A pitch on directions to improve experimental reproducibility, illustrated by examples of past experiences. I made the plee to move from 'Proudly invented here' to 'Proudly copyied from', to re-use each other's eperiences in successes and failures.
2022-09-08 ECPM Digital Biomarkers and AI, Basel, Alain van Gool.pdfAlain van Gool
Lecture for 150 pharma professionals to outline the potentials and things-to-do with digital biomarkers, as part of a ECPM training on digitization and AI in drug development.
2022-04-14 EuroMedLab, Munich, Alain van GoolAlain van Gool
Keynote lecture at the EuroMedLab 2021 providing an audience of clinical chemists and laboratory medicine scientists with advancements of multi-omics applications in personalized healthcare, and challenges that we need to solve as translational scientists.
2021 12-10 Amalia Science Day, Nijmegen, Alain van GoolAlain van Gool
This document discusses the use of omics technologies like genomics, proteomics, and glycoproteomics in pediatric healthcare. Specifically, it describes a study that used glycoproteomics to analyze blood samples from children with febrile illness to distinguish between viral and bacterial infections. The analysis identified glycoprotein biomarkers that could accurately classify 70-80% of samples as viral or bacterial. Integrating multiple omics data through machine learning approaches may provide a more comprehensive understanding of diseases and lead to personalized diagnosis and treatment.
2021 06-14 EATRIS-Plus summer school, Alain van GoolAlain van Gool
Introductory lecture for the 100 participant summer school of the EATRIS-Plus project, outlining personalized medicine, biomarker and multi-omics strategies and use cases.
2021 03-25 11th World Clinical Biomarkers & Companion Diagnostics, Alain van ...Alain van Gool
Closing keynote of a 3-day conference on clinical biomarkers and companion diagnostics, organised by Hanson Wade, outlining the power of omics approaches in healthcare and translation of inovations to impact.
2020 09-07 European Center Pharmaceutical Medicine course Biomarkers, Basel, ...Alain van Gool
Tutorial lecture on biomarkers for pharmaceutical industry R&D professionals, outlining status, potential and challenges of biomarkers in pharma, clinic and society.
2020 08-28 SensUs Event 2020 keynote, Eindhoven, Alain van GoolAlain van Gool
Closing keynote for international students participating in the SensUs Event 2020, where they designed and created a novel sensor for drug level monitoring in epilepsy treatment. Lecture outlined innovations in biomarkers in personalized health(care).
2020 02-10 European Center Pharmaceutical Medicine course - biomarkers, Basel...Alain van Gool
This document discusses biomarkers and personalized healthcare. It begins with an overview of biomarkers in the pharmaceutical industry and how they are used from drug discovery through clinical trials. It then discusses biomarkers in academic research and healthcare, and how emerging digital biomarkers could enable personalized health monitoring. The presentation identifies some translational innovation gaps, and concludes with an outlook on how biomarkers and multi-omics approaches will continue to advance personalized diagnosis and therapies.
2019 10-14 2nd Int Congress on Precision Medicine, Munich, Alain van GoolAlain van Gool
Opening lecture at the 2nd International Congress on Precision Medicine in Munich, outlining progress in omics-based biomarkers for rare diseases, biomarker innovation gaps and multi-partner initiatives to bridge those gaps to applications. Also reviewed the highlights of our recently published Handbook of Biomarkers and Precision Medicine.
2019 09-23 COST CliniMARK summerschool, Spetses, Alain van GoolAlain van Gool
Opening lecture of the COST CliniMARK summer school 'Approaches for Biomarker Discovery and Validation'. Extensive introduction in biomarker approached used in pharmaceutical industry, academic research and clinical care, and society, combined with review of biomarker innovation gaps and outlook.
Lecture describing workflows and case studies from the Translational Metabolic Laboratory @Radboudumc how to translate x-omics biomarker signatures to clinical implementation. I also highlighted new developments to join forces in the Netherlands X-omics Initiative, United for Metabolic Disease and events/book launches in the next months.
2019 03-14 Health Valley Event 2019, Nijmegen, Alain van GoolAlain van Gool
Lecture on innovations in personalized healthcare using an integrated X-omics approach towards personalized diagnostics, as part of the regional ambitious TopFit program.
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central19various
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Histololgy of Female Reproductive System.pptxAyeshaZaid1
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
share - Lions, tigers, AI and health misinformation, oh my!.pptxTina Purnat
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
Adhd Medication Shortage Uk - trinexpharmacy.comreignlana06
The UK is currently facing a Adhd Medication Shortage Uk, which has left many patients and their families grappling with uncertainty and frustration. ADHD, or Attention Deficit Hyperactivity Disorder, is a chronic condition that requires consistent medication to manage effectively. This shortage has highlighted the critical role these medications play in the daily lives of those affected by ADHD. Contact : +1 (747) 209 – 3649 E-mail : sales@trinexpharmacy.com
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxwalterHu5
In some case, your chronic prostatitis may be related to over-masturbation. Generally, natural medicine Diuretic and Anti-inflammatory Pill can help mee get a cure.
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
2018 12-04 CHAINS X-omics workshop lecture, Veldhoven, Alain van Gool
1. Innovation within the
Netherlands X-omics Initiative
Prof Alain van Gool
Professor Personalized Healthcare
Head Translational Metabolic Laboratory
Strategic advisor of the executive board
Coordinator Radboudumc Technology Centers
CHAINS 2018
4 Dec 2018, Veldhoven
6. Diagnostic progress by Whole Exome Sequencing
Human Genetics Nijmegen (Lisenka Vissers, Marcel Nelen, Han Brunner et al)
Retrospective analysis of Intellectual Disability cohort (n=150)
Sanger sequencing
Gene-by-gene
5.4 tests / patient (1-28)
Whole Exome Sequencing
All genes at once
1 test / patient
6 Alain van Gool, CHAINS 2018, Veldhoven, 4 Dec 2018
7. Next: Whole Genome Sequencing
Circus plots of Whole Genome Sequences of two metastatic cancer patients
Source: prof Edwin Cuppen, Hartwig Medical Foundation
7 Alain van Gool, CHAINS 2018, Veldhoven, 4 Dec 2018
8. Interpretation of genetic variants becomes the issue
“Functional studies can be a powerful tool in
support of pathogenicity”
Richards et al., Genet Med. (2015)17:405-24
Variant classification:
1. Benign
2. Likely benign
3. Uncertain significance
4. Likely pathogenic
5. Pathogenic
Guidelines American College of Medical Genetics and Genomics (ACMG)
More sequence data =
more unknown variants
8 Alain van Gool, CHAINS 2018, Veldhoven, 4 Dec 2018
10. Complexity in protein biology
21.000 genes
1.000.000 -2.000.000
protein forms
N-Glycosylation
Truncation
Phosphorylation
Acetylation
Ubiquitination
…
10 Alain van Gool, CHAINS 2018, Veldhoven, 4 Dec 2018
14. Genomics & Glycoproteomics
• Mass spectrometry analysis of glycoproteins in human plasma
• 1/20 microliter analysis: detection of 1.000.000 signals in one scan (1,4 Gb)
• ~40.000 peptides of which >80% contain sugar modification
• Potential to screen patients and identify new biomarkers?
500
1000
1500
2000
m/z
5 10 15 20 25 30 35 40 Time [min]
Proof of principle study:
Biomarkers !?
Hans Wessels, Alain van Gool, Dirk Lefeber
14 Alain van Gool, CHAINS 2018, Veldhoven, 4 Dec 2018
15. Functional genomics
functional validation
of variants with unknown
significance
CRISPR/Cas9
rescue
biomarkers
animal model
iPSC
+nGFP +nGFP +TAZ
contr BTH BTH
PTPS deficiency PTPS deficiency-Corr#1
TH/βIII-tubulin/DAPI
complementation
Control clpb MO
mdh1Δ
mdh1-P128L
mdh1-P202L
mdh1-G30R
hMDH2
MDH1
-
YPD
fermentation
YPD
respiration
α-actinin
α-ManNAc
CH3
β-ManNAc
CH3
2.10 2.05 2.00
{Rodenburg,
J Inherit Metab Dis, 2018}
micro-organism model
Richard Rodenburg
Omar Tutakhel
15 Alain van Gool, CHAINS 2018, Veldhoven, 4 Dec 2018
16. Precision medicine in genetic-metabolic disease – current
Personalized diagnosis
Genomics
(WES)
Metabolomics
(IEM panel)
New disease
mechanisms
Personalized therapies
Nature Genetics 2018
NEJM 2014
Nature 2016
NEJM 2014
Genet Med 2017
16 Alain van Gool, CHAINS 2018, Veldhoven, 4 Dec 2018
19. Precision medicine in genetic-metabolic disease - future
Personalized diagnosis
Genomics
(WGS)
Metabolomics
(more panels)
New personalized
therapies
Glycomics
Glycoproteomics
Deep Learning
Artificial Intelligence
System biology
Nature Genetics 2016 Pilot 2017
New disease
mechanisms
19 Alain van Gool, CHAINS 2018, Veldhoven, 4 Dec 2018
20. Progress further through collaboration
European networks
national
local
20 Alain van Gool, CHAINS 2018, Veldhoven, 4 Dec 2018
23. 23 Alain van Gool, CHAINS 2018, Veldhoven, 4 Dec 2018
24. Netherlands X-omics Initiative
Push omics
technologies
• Resolution
• Sensitivity
• Coverage
Genomics
Proteomics
Metabolomics
• Quality
• Standards
• Data FAIR
at source
X-omics
• Study design
• Sample handling
• Data cataloging
• Quality
• Expertise
• Best practice
• Data integration
• Data analysis
• Best practice
• Access
• Helpdesk / training
• Collaboration
24 Alain van Gool, CHAINS 2018, Veldhoven, 4 Dec 2018
25. X-omics demonstrators
www.x-omics.nl
1. Cell/organoid
• Understanding cancer drug response and resistance
• Drug-induced dynamic pathway analysis
2. Individual
• Understanding personalized differences in rare diseases
• Systemic changes to biological challenges
3. Population
• Understanding genetic variants in Dutch population
• Statistical correlations
To showcase and field test new X-omics capabilities
25 Alain van Gool, CHAINS 2018, Veldhoven, 4 Dec 2018
26. Objectives next years
www.x-omics.nl26 Alain van Gool, Benelux Precision Medicine Forum, Utrecht, 13 June 2018
1. Advancing X-omics technologies far
beyond state-of-the-art
2. Realizing a genuinely integrated X-omics
infrastructure in Netherlands
3. Use infrastructure for new biology
Consortium kick-off
Nijmegen, 14 Sept 2018
Other
networks,
infrastructures,
cohorts,
projects
27. Acknowledgements
Translational Metabolic Laboratory
Hans Wessels
Dirk Lefeber
Karlien Coene
Leo Kluijtmans
Richard Rodenburg
Jolein Gloerich
Anouk Suppers
Purva Kulkarni
Albert Gerritsen
Roel Tans
Esther Willems
Ron Wevers
and others
Edwin Cuppen
Albert Heck
Thomas Hankemeier
Peter Bram ‘t Hoen
Daniella Kasteel
and others
Collaborators/funders
Human Genetics Nijmegen
Marcel Nelen
Alexander Hoischen
Lisenka Vissers
Christian Gillisen
Han Brunner
and others
alain.vangool@radboudumc.nl
www.radboudumc.nl/en/people/alain-van-gool
www.slideshare.net/alainvangool
CarTarDis
Irene Keularts
Hans Scheffer
and others
Rainer Bischoff
Theo Luider
and others